Skip to main content
Equibles
ZVRA logo

ZVRA · Zevra Therapeutics, Inc. · Metrics

Track ZVRA — free

Use ZVRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZVRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.33 -0.03 (-0.29%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Market Cap
$614.03M
Shares
59.38M
Volume · Oct 22 537.3K Avg daily vol (3M) 1.05M

ZVRA metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.33
Market cap
$614.03M

Price action

20 metrics
Price change (1W)
+0.6%
Price change (30D)
-10.8%
Price change (3M)
-17.5%
Price change (6M)
+2.2%
Price change (YTD)
+15.3%
Price change (1Y)
-4.0%
Trailing year
Price change (5Y)
+2.4%
52-week high
$14.75
52-week low
$8.10
Change from 52-week high
-30.0%
Change from 52-week low
+27.5%
Annualized volatility
60.1%
Annualized volatility (3M)
68.7%
Beta
1.0
RSI (14D)
42.2
Price vs SMA 50
-9.1%
Price vs SMA 200
-3.5%
Avg volume (3M)
1.05M
Relative volume
0.5
Average dollar volume
$11.50M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
59.38M

Valuation

12 metrics
P / E (TTM)
11.0
Trailing earnings · reciprocal yield 9.1%
PEG ratio
—
EV / revenue
3.4×
reciprocal yield 29.0%
EV / EBITDA
5.6×
reciprocal yield 17.9%
EV / EBIT
5.7×
reciprocal yield 17.6%
P / sales
4.5×
reciprocal yield 22.2%
P / book
2.8
reciprocal yield 35.4%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
18.4
reciprocal yield 5.4%
Earnings yield
9.5%

Historical valuation

8 metrics
P / E historical average (3Y)
10.9×
reciprocal yield 9.2%
P / E historical average (5Y)
10.9×
reciprocal yield 9.2%
EV / revenue historical average (3Y)
6.5×
reciprocal yield 15.3%
EV / revenue historical average (5Y)
8.5×
reciprocal yield 11.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-03
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
60.5%
Trailing 12 months
Net margin
42.8%
Gross profit (TTM)
$24.52M
Operating profit (TTM)
$82.38M
Net income (TTM)
$58.26M
Trailing 12 months
Diluted EPS (TTM)
$0.94
FCF margin
—
Effective tax rate
15.9%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.72

Growth

11 metrics
Revenue growth YoY
+53.3%
Year over year
Net income growth YoY
-88.3%
Revenue (TTM)
$136.07M
Trailing 12 months
EPS growth YoY
-88.4%
Shares change YoY
+8.9%
Year over year · more shares
Revenue CAGR (3Y)
+118.8%
Revenue CAGR (5Y)
+51.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
26.8%
Return on assets
19.2%
Debt / equity
0.0
Current ratio
5.2
EBITDA (TTM)
$83.87M
Free cash flow (TTM)
—
Quick ratio
5.1
Interest coverage
14.4
Net debt / EBITDA
-1.7
Return on invested capital
95.8%
Trailing 12 months
Net cash
$145.32M
Latest balance sheet
Cash & equivalents
$145.32M
Total assets
$302.71M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$33.40M
Capital expenditures (TTM)
$775,000
R&D (TTM)
$14.93M
SG&A (TTM)
$74.63M
Stock compensation (TTM)
$13.13M
R&D / revenue
11.0%
Stock compensation / revenue
9.6%

Ownership (13F)

9 metrics
13F filers
157
13F filer change QoQ
+9
Institutional ownership
80.8%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
28.0%
Private-fund adviser ownership
25.0%
Active holders' share change QoQ
+7.7%
Holder tenure
10.6
Price vs estimated holder cost
+64.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.9%

Short interest

3 metrics
Short interest
12.0%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
81 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$838,100
Insider-sentiment score
45 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1434647 CUSIP 488445206 13F (30d) 22 filings 22 filers Visit website Investor relations